The judgment of the Court of Cassation of 6 December 2017, in the case between TEVA and MERCK (patent owner), is the outcome of a long and complex affair concerning the nullity of the French part of the European Patent (EP) n°0724444 describing a dosage regime.
Professor Daryl Lim, keynote speaker at Novagraaf’s January event ‘An Evening at the Embassy’ in Washington, DC, on the importance of fostering understanding and dialogue between IP stakeholders.
Although its implementation date continues to be delayed, the proposed Unitary Patent system promises a simpler and more cost-effective route to patent protection in and across the EU member states. We set out the answers to some frequently asked questions.
IP strategy is best considered at the start of research and development (R&D). The first step is choosing the IP approach to take during product development. Novagraaf’s Mark Suddaby explains the options.
The research and development (R&D) process can require considerable investment in both time and money.